TrialClinical pharmacology in drug development2020

First-in-Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers.

Jonathan C Fox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.